Lv4
730 积分 2024-01-11 加入
Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory Waldenström macroglobulinemia: results from the Phase 1/2 BRUIN study
10天前
已关闭
Luvometinib: First Approval
28天前
已完结
Epidemiology, treatment patterns and survival of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) in Taiwan, 2006-2015
2个月前
已完结
Epidemiology, treatment patterns and survival of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) in Taiwan, 2006-2015
2个月前
已完结
Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission
3个月前
已完结
SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions
3个月前
已完结
Azacitidine maintenance in AML post induction and posttransplant
3个月前
已完结
Evaluating the concordance between BICLA and SRI4 in patients with systemic lupus erythematosus from the placebo arms of the EXPLORER and ATHOS trials
3个月前
已完结
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review
3个月前
已完结
Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma
3个月前
已完结
皖公网安备34019202002308
